

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		AT	ATTORNEY DOCKET NO.	
09/476,253	12/30/99	WATSON		J	PC9731A	
			¬ [EX	AMINER	
023913 PFIZER INC 235 E 42ND	STREET	HM22/0705		DEL ACRI ART UNIT	TX MUTCHET J PAPER NUMBER	
NEW YORK N	Y 10017			1614		
				DATE MAILED:	07/05/01	

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks



Office Action Summary

ĭ

Application No. 09/476,253

Examiner

Applicant(s)

Art Unit

WATSON et al.



1614 Cybille Delacroix-Muirheid -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address -Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 2b) This action is non-final. 2a) This action is FINAL. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213. Disposition of Claims is/are pending in the application. 4) X Claim(s) 1-41 4a) Of the above, claim(s) _______ is/are withdrawn from consideration. 5) Claim(s) 6) Claim(s) _____ is/are rejected. 7) Claim(s) is/are objected to. 8) Claims 1-41 are subject to restriction and/or election requirement. **Application Papers** 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are objected to by the Examiner. 11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved. 12) The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. § 119 13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). *See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e). Attachment(s) 15) Notice of References Cited (PTO-892) 18) Interview Summary (PTO-413) Paper No(s). 19) Notice of Informal Patent Application (PTO-152) 16) Notice of Draftsperson's Patent Drawing Review (PTO-948)

17) Information Disclosure Statement(s) (PTO-1449) Paper No(s).

20) Other:

Application/Control Number: 09/476,253 Page 2

Art Unit: 1614

SUPPLEMENTAL DETAILED ACTION

Due to the complex nature of the claims, no request for an oral election is being made. Please see MPEP 812.01.

Upon further consideration of the pending claims, the following supplemental election is being submitted.

Election/Restriction

1. This application contains claims directed to the following patentably distinct species of the claimed invention: a method for treating or preventing stasis in all or parts of the stomach of a patient comprising administering either a compound of (I) Formula IA or a compound of (2) Formula IB. Applicant is to elect either Formula IA or Formula IB. Moreover, substituents R²_a and R²_b are hydrogen or the moieties described in Sections I-V. Applicant is requested to elect a single species described in either Section I or Section II or Section IV or Section V. Finally, concerning claims 28 and 29, Applicant is to elect a single auxiliary therapeutic agent, and with respect to claims 40 and 41, Applicant is to elect a single therapeutic agent.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1, 11, 19, 30, 40 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an

Application/Control Number: 09/476,253

Art Unit: 1614

allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must

Page 3

indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant

should submit evidence or identify such evidence now of record showing the species to be obvious variants

or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the

inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35

U.S.C. 103(a) of the other invention.

Applicant is advised that the reply to this requirement to be complete must include an election of

the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the 2.

inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named

inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of

inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37

CFR 1.17(I).

Any inquiry concerning this communication or earlier communications from the examiner should be 3.

directed to Cybille Delacroix-Muirheid whose telephone number is (703) 306-3227.

June 27, 2001